Logo

RGC

Regencell Bioscience Holdings Limited

RGC

Regencell Bioscience Holdings Limited • NASDAQ
$11.53 ▲ 3.78% (+0.42)
Market Cap $5.70 B
52w High $83.60
52w Low $0.09
Dividend Yield 0%
P/E -1153
Volume 166.82K
Outstanding Shares 494.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $1.978M ▲ $-1.854M ▼ 0% $-0.14 ▼ $-1.777M ▼
Q4-2024 $0 $1.212K ▲ $-1.117K ▼ 0% $0 ▲ $-1.139K ▲
Q2-2024 $0 $1.156K ▼ $-1.033K ▲ 0% $-0 ▲ $-1.156M ▲
Q4-2023 $0 $2.076M ▼ $-2.645M ▲ 0% $-0.005 ▲ $-3.361M ▲
Q2-2023 $0 $3.431M $-3.229M 0% $-0.007 $-5.03M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $0 ▼ $7.479M ▼ $763.839K ▲ $6.715M ▼
Q4-2024 $7.961M ▲ $8.438M ▼ $219.512K ▼ $8.219M ▼
Q2-2024 $4.8M ▼ $10.475M ▼ $312.554K ▼ $10.163M ▼
Q4-2023 $11.565M ▲ $12.622M ▼ $632.32K ▼ $12.03M ▼
Q2-2023 $0 $15.548M $873.789K $14.659M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-1.852K ▲ $0 ▲ $0 ▼ $0 ▼ $0 ▼ $0 ▲
Q4-2024 $-2.182M $-2.001M $2.621M $51.141K $1.396M $-2.004M
Q2-2024 $-2.182M ▲ $-2.001M ▲ $2.621M ▲ $51.141K ▼ $1.396M ▲ $-2.004M ▲
Q4-2023 $-2.936M $-2.481M $29.489K $67.457K $-4.852M $-2.495M
Q2-2023 $-2.936M $-2.481M $29.489K $67.457K $-4.852M $-2.495M

Five-Year Company Overview

Income Statement

Income Statement Regencell is still a pre‑revenue company. It has not yet generated meaningful sales, so its income statement mainly reflects research, admin, and listing costs rather than a running business. Losses so far appear modest in absolute size, but the key point is that there is no operating revenue to offset these expenses. The business is essentially in a long development phase, with future profitability entirely dependent on successful product approvals and commercialization, which remain uncertain.

Balance Sheet

Balance Sheet The balance sheet looks very light: small asset levels, mainly cash and related items, no meaningful physical assets, and no debt reported. The company is equity‑funded and carries a thin capital base, which limits financial flexibility. The lack of debt reduces financial risk on the downside, but the modest asset and equity levels underline that this is still a very small, early‑stage platform rather than a scaled healthcare business. Any larger clinical, regulatory, or commercial push will likely require additional capital over time.

Cash Flow

Cash Flow Cash flows reflect an early R&D company: no inflows from customers and small, recurring outflows to fund operations. Historically, operating cash burn appears low in absolute terms, and there is essentially no investment in heavy equipment or facilities. That said, with no internal cash generation, the company depends on external funding to sustain activities. As development progresses, cash needs could rise meaningfully, so future financings and dilution risk are important points to watch.

Competitive Edge

Competitive Edge Regencell’s competitive position rests on a narrow and differentiated niche: Traditional Chinese Medicine‑based treatments for ADHD and autism. This gives it a distinct profile versus conventional Western drug developers and positions it as an early mover in standardized TCM for neurocognitive disorders. However, the competitive moat is still fragile. Its core theory and formulas are not yet broadly validated in mainstream science, clinical data sets are small, and there appears to be limited patent protection around specific formulations. Larger pharmaceutical and TCM players could move into the same space if the opportunity proves attractive, so long‑term defensibility is uncertain and will hinge on robust data, regulatory recognition, and brand trust.

Innovation and R&D

Innovation and R&D Innovation is where the company is strongest on story but also riskiest in execution. Its work is built around a proprietary TCM brain theory and standardized herbal formulas targeted at ADHD, autism, and previously COVID‑19. Early internal trials and case studies suggest potential benefits, but these studies are small and rely heavily on the company’s own assessment tools. The crucial next steps are larger, well‑designed, and independently assessed clinical trials, plus clear regulatory paths in Asia and possibly Western markets. Progress on patents, peer‑reviewed publications, and regulatory filings will be key signals of whether its R&D can translate into widely accepted medical products.

Summary

Regencell is best viewed as a very early‑stage, high‑uncertainty biotech concept rather than an established healthcare business. Financially, it has no revenue, small ongoing losses, a very light balance sheet, and relies on external capital to fund operations. Strategically, it is pursuing a distinctive, TCM‑based approach to neurocognitive disorders, which offers differentiation but also faces major scientific, regulatory, and competitive questions. Future value will depend heavily on clinical trial results, regulatory approvals, intellectual property strength, and the company’s ability to finance itself through a long development journey. The profile is inherently speculative, with outcomes likely to be binary over the long term.

NEWS

November 24, 2025 · 4:44 PM UTC

RGC Resources, Inc. Raises Annual Dividend to $0.87 Per Share

Read more

November 20, 2025 · 2:00 PM UTC

RGC Resources, Inc. Schedules Fourth Quarter 2025 Earnings Call

Read more

November 20, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC

Read more

November 19, 2025 · 4:57 PM UTC

RGC Resources, Inc. Reports 2025 Earnings

Read more

September 29, 2025 · 5:00 PM UTC

RGC Resources, Inc. Declares Quarterly Dividend

Read more